The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations

Kyle Higgins, Olga P. Nyssen, Joshua Southern, Ivan Laponogov, Dennis Veselkov, Javier P. Gisbert (), Tania Fleitas Kanonnikoff () and Kirill Veselkov ()
Additional contact information
Kyle Higgins: Imperial College London
Olga P. Nyssen: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)
Joshua Southern: Imperial College London
Ivan Laponogov: Imperial College London
Dennis Veselkov: Imperial College London
Javier P. Gisbert: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD)
Tania Fleitas Kanonnikoff: Hospital Clínico Universitario de Valencia
Kirill Veselkov: Imperial College London

Nature Communications, 2025, vol. 16, issue 1, 1-12

Abstract: Abstract Helicobacter pylori (H. pylori) is the most common carcinogenic pathogen globally and the leading cause of gastric cancer. Here, we develop a reinforcement learning-based AI Clinician system to personalise treatment selection and evaluate its ability to improve eradication success compared to clinician-prescribed therapies. The model is trained and internally validated on 38,049 patients from the retrospective European Registry on Helicobacter pylori Management (Hp-EuReg), using independent state deep Q-learning (isDQN) to recommend optimal therapies based on patient characteristics such as age, sex, antibiotic allergies, country, and pre-treatment indication. In internal validation using real-world Hp-EuReg data, AI-recommended therapies achieve a 94.1% success rate (95% CI: 93.2–95.0%) versus 88.1% (95% CI: 87.7–88.4%) for clinician-prescribed therapies not aligned with AI suggestions—an improvement of 6.0%. Results are replicated in an external validation cohort (n = 7186), confirming generalisability. The AI system identifies optimal treatment strategies in key subgroups: 65% (n = 24,923) are recommended bismuth-based therapies, and 15% (n = 5898) non-bismuth quadruple therapies. Random forest modelling identifies region and concurrent medications as patient-specific drivers of AI recommendations. With nearly half the global population likely to contract H. pylori, this approach lays the foundation for future prospective clinical validation and shows the potential of AI to support clinical decision-making, enhance outcomes, and reduce gastric cancer burden.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-61329-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61329-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-61329-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().